price

A federal appeals court has unanimously rejected Novo Nordisk’s challenge to Medicare’s drug price negotiation program, a ruling that will allow the government to group products containing the same ingredient together for the purpose of choosing which drugs to negotiate. The pharmaceutical industry is on a losing streak on this issue, at least in the […]